T he American Diabetes Association's (ADA's) Standards of Medical Care in Diabetes is updated and published annually in a supplement to the January issue of Diabetes Care. The ADA's Professional Practice Committee, comprised of physicians, diabetes educators, registered dietitians, and public health experts, develops the Standards. Formerly called Clinical Practice Recommendations, the Standards includes the most current evidence-based recommendations for diagnosing and treating adults and children with all forms of diabetes. ADA's grading system uses A, B, C, or E to show the evidence level that supports each recommendation.
• A-Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered • B-Supportive evidence from well-conducted cohort studies • C-Supportive evidence from poorly controlled or uncontrolled studies • E-Expert consensus or clinical experience This is an abridged version of the current Standards containing the evidence-based recommendations most pertinent to primary care. The tables and figures have been renumbered from the original document to match this version. The complete 2017 Standards of Care document, including all supporting references, is available at professional.diabetes. org/standards.
PROMOTING HEALTH AND REDUCING DISPARITIES IN POPULATIONS

Recommendations
• Treatment plans should align with the Chronic Care Model, emphasizing productive interactions between a prepared proactive practice team and an informed activated patient. A • When feasible, care systems should support team-based care, community involvement, patient registries, and decision support tools to meet patient needs. B
Diabetes and Population Health
Clinical practice guidelines are key to improving population health; however, for optimal outcomes, diabetes care must be individualized for each patient. Thus, efforts to improve population health will require a combination of systems-level and patient-level approaches. With such an integrated approach in mind, the ADA highlights the importance of patient-centered care, defined as care that is respectful of and responsive to individual patient preferences, needs, and values and ensuring that patient values guide all clinical decisions.
Care Delivery Systems
Despite the many advances in diabetes care, 33-49% of patients still do not meet targets for glycemic, blood pressure, or cholesterol control, and only 14% meet targets for all three measures while also avoiding smok-ing. Certain segments of the population, such as young adults and patients with complex comorbidities, financial or other social hardships, and/or limited English proficiency, face particular challenges to care. Even after adjusting for these factors, the persistent variability in the quality of diabetes care across providers and practice settings indicates that substantial system-level improvements are still needed.
Chronic Care Model
Numerous interventions to improve adherence to the recommended standards have been implemented. However, a major barrier to optimal care is a delivery system that is often fragmented, lacks clinical information capabilities, duplicates services, and is poorly designed for the coordinated delivery of chronic care. The Chronic Care Model (CCM) takes these factors into consideration and is an effective framework for improving the quality of diabetes care.
Six Core Elements
The CCM includes six core elements to optimize the care of patients with chronic disease: 1. Delivery system design (moving from a reactive to a proactive care delivery system where planned visits are coordinated through a team-based approach) 2. Self-management support 3. Decision support (basing care on evidence-based, effective care guidelines) 4. Clinical information systems (using registries that can provide patient-specific and population-based support to the care team) 5. Community resources and policies (identifying or developing resources to support healthy lifestyles) 6. Health systems (to create a quality-oriented culture)
Redefining the roles of the health care delivery team and empowering patient self-management are fundamental to the successful implementation of the CCM. Collaborative, multidisciplinary teams are best suited to provide care for people with chronic conditions such as diabetes and to facilitate patients' selfmanagement.
Strategies for System-Level Improvement
Optimal diabetes management requires an organized, systematic approach and the involvement of a coordinated team of dedicated health care professionals working in an environment where patient-centered, high-quality care is a priority. Three objectives to achieve this include: 1. Optimizing provider and team behavior 2. Supporting patient self-management 3. Changing the care system
Tailoring Treatment to Reduce Disparities
Social determinants of health can be defined as the economic, environmental, political, and social conditions in which people live and are responsible for a major part of health inequality worldwide. Given the tremendous burden that obesity, unhealthy eating, physical inactivity, and smoking place on the health of patients with diabetes, efforts are needed to address and change the societal determinants of these problems.
Recommendations
• Providers should assess social context, including potential food insecurity, housing stability, and financial barriers, and apply that information to treatment decisions. A • Patients should be referred to local community resources when available. B • Patients should be provided with self-management support from lay health coaches, navigators, or community health workers when available. A
CLASSIFICATION AND DIAGNOSIS OF DIABETES
Diabetes can be classified into the following general categories: 1. Type 1 diabetes (due to autoimmune β-cell destruction, usually leading to absolute insulin deficiency) 2. Type 2 diabetes (due to a progressive loss of β-cell insulin secretion frequently on the background of insulin resistance) 3. Gestational diabetes mellitus (GDM) (diabetes diagnosed in the second or third trimester of pregnancy that is not clearly overt diabetes prior to gestation) In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).
*In the absence of unequivocal hyperglycemia, results should be confirmed by repeat testing. a b r i d g e d s ta n d a r d s o f c a r e 2017
4. Other specific types, including monogenic forms of diabetes
Diagnostic Tests for Diabetes
Diabetes may be diagnosed based on plasma glucose criteria-either the fasting plasma glucose (FPG) or the 2-h plasma glucose value after a 75-g oral glucose tolerance test (OGTT) -or A1C (Table 1) . The same tests are used to screen for and diagnose diabetes and to detect individuals with prediabetes (Table 2) . Prediabetes is defined as FPG of 100-125 mg/dL (5.6-6.9 mmol/L); 2-h OGTT of 140-199 mg/dL (7.8-11 .0 mmol/L); or A1C of 5.7-6.4% (39-47 mmol/mol). 
COMPREHENSIVE MEDICAL EVALUATION AND ASSESSMENT OF COMORBIDITIES
The comprehensive medical evaluation includes the initial and ongoing evaluations, assessment of complications, management of comorbid conditions, and engagement of the patient throughout the process. People with diabetes should receive health care from a team that may include physicians, nurse practitioners, physician assistants, nurses, dietitians, exercise specialists, pharmacists, dentists, podiatrists, and mental health professionals. Individuals with diabetes must assume an active role in their care. The patient, family, physician, and health care team should formulate the management plan, which includes lifestyle management. Lifestyle management and psychosocial care are the cornerstones of diabetes management. Patients should be referred for diabetes self-management education (DSME), diabetes self-management support (DSMS), medical nutrition therapy (MNT), and psychosocial/emotional health concerns if indicated. Additional referrals should be arranged as necessary (Table 3) . Patients should receive recommended preventive care services (e.g., immunizations and cancer screening); smoking cessation counseling; and ophthalmological, dental, and podiatric referrals. Clinicians should ensure that individuals with diabetes are appropriately screened for complications and comorbidities.
Comprehensive Medical Evaluation
The components of the comprehensive diabetes medical evaluation are listed in Table 4 .
Recommendations
A complete medical evaluation should be performed at the initial visit to • Confirm the diagnosis and classify diabetes. B • Presence of common comorbidities and dental disease
• Screen for depression, anxiety, and disordered eating using validated and appropriate measures**
• Screen for diabetes distress using validated and appropriate measures**
• Screen for psychosocial problems and other barriers to diabetes self-management such as limited financial, logistical, and support resources
• History of tobacco use, alcohol consumption, and substance use
• DSME and DSMS history and needs
• Review of previous treatment regimens and response to therapy (A1C records)
• Assess medication-taking behaviors and barriers to medication adherence
• Results of glucose monitoring and patient's use of data
• DKA frequency, severity, and cause
• Hypoglycemia episodes, awareness, frequency, and causes
• History of increased blood pressure and abnormal lipids
• Microvascular complications: retinopathy, nephropathy, and neuropathy (sensory, including history of foot lesions; autonomic, including sexual dysfunction and gastroparesis)
• Macrovascular complications: coronary heart disease, cerebrovascular disease, and peripheral arterial disease
• For women with child-bearing capacity, review contraception and preconception planning
Physical examination
• Height, weight, and BMI; growth and pubertal development in children and adolescents
• Blood pressure determination, including orthostatic measurements when indicated
• Fundoscopic examination
• Thyroid palpation
• Skin examination (e.g., for acanthosis nigricans and insulin injection or infusion set insertion sites)
• Comprehensive foot examination: 
Cognitive Impairment/ Dementia
Diabetes is associated with a significantly increased risk and rate of cognitive decline and an increased risk of dementia. In a 15-year prospective study of community-dwelling people >60 years of age, the presence of diabetes at baseline significantly increased the age-and sex-adjusted incidence of all-cause dementia, Alzheimer's disease, and vascular dementia compared with rates in those with normal glucose tolerance.
Fatty Liver Disease
Elevations of hepatic transaminase concentrations are associated with higher BMI, waist circumference, and triglyceride levels and lower HDL cholesterol levels. In a prospective analysis, diabetes was significantly associated with incident nonalcoholic chronic liver disease and with hepatocellular carcinoma. Interventions that improve metabolic abnormalities in patients with diabetes (weight loss, glycemic control, and treatment with specific drugs for hyperglycemia or dyslipidemia) are also beneficial for fatty liver disease.
Fractures
Age-specific hip fracture risk is significantly increased in people with both type 1 (relative risk 6.3) and type 2 (relative risk 1.7) diabetes in both sexes. Type 1 diabetes is associated with osteoporosis, but in type 2 diabetes, an increased risk of hip fracture is seen despite higher bone mineral density.
Hearing Impairment
Hearing impairment, both in highfrequency and low-to mid-frequency ranges, is more common in people with diabetes than in those without, perhaps due to neuropathy and/ or vascular disease.
Low Testosterone in Men
Mean levels of testosterone are lower in men with diabetes compared with age-matched men without diabetes, but obesity is a major confounder. Treatment in asymptomatic men is controversial. The evidence that testosterone replacement affects outcomes is mixed, and recent guidelines do not recommend testing or treating men without symptoms.
Obstructive Sleep Apnea
Age-adjusted rates of obstructive sleep apnea, a risk factor for cardiovascular disease (CVD), are significantly higher (4-to 10-fold) with obesity, and especially with central obesity.
The prevalence of obstructive sleep apnea in the population with type 2 diabetes may be as high as 23%, and the prevalence of any sleep disordered breathing may be as high as 58%.
Periodontal Disease
Periodontal disease is more severe and may be more prevalent in people with diabetes than in those without. Current evidence suggests that periodontal disease adversely affects diabetes outcomes, although evidence for treatment benefits on diabetes control remains unclear.
Psychosocial Disorders
Prevalence of clinically significant psychopathology in people with diabetes ranges across diagnostic categories, and some diagnoses are considerably more common in people with diabetes than for those without the disease. Lifestyle management is a fundamental aspect of diabetes care and includes DSME and DSMS, nutrition, physical activity, smoking cessation, and psychosocial care.
DSME and DSMS
Recommendations
• In accordance with the national standards for DSME and DSMS, all people with diabetes should participate in DSME to facilitate the knowledge, skills, and ability necessary for diabetes self-care and in DSMS to assist with implementing and sustaining skills and behaviors needed for ongoing The overall objectives of DSME and DSMS are to support informed decision-making, self-care behaviors, problem-solving, and active collaboration with the health care team to improve clinical outcomes, health status, and quality of life in a costeffective manner.
Four critical time points have been defined when the need for DSME and DSMS should be evaluated by the medical care provider and/or multidisciplinary team, with referrals made as needed: 
A
Eating patterns and macronutrient distribution
• Because there is no single ideal dietary distribution of calories among carbohydrates, fats, and proteins for people with diabetes, macronutrient distribution should be individualized while keeping total caloric and metabolic goals in mind.
E
• A variety of eating patterns are acceptable for the management of type 2 diabetes and prediabetes including the Mediterranean diet, DASH, and plant-based diets.
B
• Carbohydrate intake from whole grains, vegetables, fruits, legumes, and dairy products, with an emphasis on foods higher in fiber and lower in glycemic load, should be advised over other sources, especially those containing sugars.
• People with diabetes and those at risk should avoid sugar-sweetened beverages to control weight and reduce their risk for CVD and fatty liver disease B and should minimize their consumption of foods with added sugar that have the capacity to displace healthier, more nutrient-dense food choices. A B, A Protein • In individuals with type 2 diabetes, ingested protein appears to increase insulin response without increasing plasma glucose concentrations. Therefore, carbohydrate sources high in protein should not be used to treat or prevent hypoglycemia.
Dietary fat
• Whereas data on the ideal total dietary fat content for people with diabetes are inconclusive, an eating plan emphasizing elements of a Mediterranean-style diet rich in monounsaturated fats may improve glucose metabolism and lower CVD risk and can be an effective alternative to a diet low in total fat but relatively high in carbohydrates.
B
• Eating foods rich in long-chain ω-3 fatty acids, such as fatty fish (EPA and DHA) and nuts and seeds (ALA) is recommended to prevent or treat CVD B; however, evidence does not support a beneficial role for ω-3 
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Nutrition Therapy
For many individuals with diabetes, the most challenging part of the treatment plan is determining what to eat and following a food plan.
There is not a one-size-fits-all eating pattern for individuals with diabetes. The Mediterranean diet, Dietary Approaches to Stop Hypertension (DASH) diet, and plant-based diets are all examples of healthful eating patterns. See Table 5 for specific nutrition recommendations. In overweight and obese patients with type 2 diabetes, modest weight loss, defined as sustained reduction of 5% of initial body weight, has been shown to improve glycemic control and to reduce the need for glucose-lowering medications. However, sustaining weight loss can be challenging. Weight loss can be attained with lifestyle programs that achieve a 500-750 kcal/day energy deficit or provide ~1,200-1,500 kcal/day for women and 1,500-1,800 kcal/day for men, adjusted for the individual's baseline body weight. 
Exercise in the Presence of Specific Long-Term Complications of Diabetes
Retinopathy
If proliferative diabetic retinopathy or severe nonproliferative diabetic retinopathy is present, then vigorous-intensity aerobic or resistance exercise may be contraindicated because of the risk of triggering vitreous hemorrhage or retinal detachment. Consultation with an ophthalmologist prior to engaging in an intense exercise regimen may be appropriate.
Peripheral Neuropathy
Decreased pain sensation and a higher pain threshold in the extremities result in an increased risk of skin breakdown, infection, and Charcot joint destruction with some forms of exercise. Therefore, a thorough assessment should be done to ensure that neuropathy does not alter kinesthetic or proprioceptive sensation during physical activity, particularly in those with more severe neuropathy. C Alcohol • Adults with diabetes who drink alcohol should do so in moderation (no more than one drink per day for adult women and no more than two drinks per day for adult men).
C
• Alcohol consumption may place people with diabetes at increased risk for hypoglycemia, especially if they are taking insulin or insulin secretagogues. Education and awareness regarding the recognition and management of delayed hypoglycemia are warranted.
B
Sodium
• As for the general population, people with diabetes should limit sodium consumption to <2,300 mg/day, although further restriction may be indicated for those with both diabetes and hypertension.
B
Nonnutritive Sweeteners
• The use of nonnutritive sweeteners has the potential to reduce overall caloric and carbohydrate intake if substituted for caloric sweeteners and without compensation by intake of additional calories from other food sources. Nonnutritive sweeteners are generally safe to use within the defined acceptable daily intake levels. The complete 2017 Standards of Care includes additional goals for children and pregnant women.
Glycemic control achieved using A1C targets of <7% (53 mmol/mol) has been shown to reduce microvascular complications of diabetes, and, in type 1 diabetes, mortality. There is evidence for cardiovascular benefit of intensive glycemic control after long-term follow-up of people treated early in the course of type 1 and type 2 diabetes; however, optimal A1C targets should be individualized based on several patient-specific and disease-specific factors (Figure 1 ). Recommended glycemic targets are provided in Table 6 . The recommendations include blood glucose levels that appear to correlate with achievement of an A1C of ≤7% (53 mmol/mol).
Hypoglycemia
The 2017 Standards of Care provides a new classification of hypoglycemia.
Recommendations
• Individuals at risk for hypoglycemia should be asked about symptomatic and asymptomatic hypoglycemia at each encounter. Obesity management can delay progression from prediabetes to type 2 diabetes and may be beneficial in the treatment of type 2 diabetes. In overweight and obese patients with type 2 diabetes, modest and sustained weight loss has been shown to improve glycemic control and to reduce the need for glucose-lowering medications.
Assessment
Recommendation
• At each patient encounter, BMI should be calculated and documented in the medical record. B
In Asian Americans, the BMI cutoff points to define overweight and obesity are lower than in other populations.
Providers should advise overweight and obese patients that higher BMIs increase the risk of CVD and all-cause mortality.
Providers should assess each patient's readiness to achieve weight loss and jointly determine weight loss goals and intervention strategies.
Diet, Physical Activity, and Behavioral Therapy
Recommendations
• Diet, physical activity, and behavioral therapy designed to achieve >5% weight loss should be prescribed for overweight and obese patients with type 2 diabetes ready to achieve weight loss. A • Such interventions should be high intensity (≥16 sessions in 6 months) and focus on diet, physical activity, and behavioral strategies to achieve a 500 Figure 2 and Figure 3 outline monotherapy and combination therapy emphasizing drugs commonly used in the United States and/or Europe.
CVD AND RISK MANAGEMENT
ASCVD is the leading cause of morbidity and mortality for individuals with diabetes and is the largest contributor to the direct and indirect costs of diabetes. In all patients with diabetes, cardiovascular risk factors should be systematically assessed at least annually. These risk factors include hypertension, dyslipidemia, smoking, family history of premature coronary disease, and albuminuria. Large benefits are seen when multiple risk factors are addressed simultane-
ously. There is evidence that measures of 10-year coronary heart disease risk among U.S. adults with diabetes have improved significantly over the past decade and that ASCVD morbidity and mortality have decreased.
Blood Pressure Control
Recommendations
• Blood pressure should be measured at every routine visit. A1C is greater than or equal to 9%, consider Dual Therapy.
A1C is greater than or equal to 10%, blood glucose is greater than or equal to 300 mg/dL, or patient is markedly symptomatic, consider Combination Injectable Therapy (See Figure 3) .
■ FIGURE 2. Antihyperglycemic therapy in type 2 diabetes: general recommendations. The order in the chart was determined by historical availability and the route of administration, with injectables to the right; it is not meant to denote any specific preference. Potential sequences of antihyperglycemic therapy for patients with type 2 diabetes are displayed, with the usual transition moving vertically from top to bottom (although horizontal movement within therapy stages is also possible, depending on the circumstances). DPP-4-i, DPP-4 inhibitor; fxs, fractures; GI, gastrointestinal; GLP-1 RA, GLP-1 receptor agonist; GU, genitourinary; HF, heart failure; Hypo, hypoglycemia; SGLT2-i, SGLT2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione. *See original source for description of efficacy categorization. §Usually a basal insulin (NPH, glargine, detemir, degludec). Adapted with permission from Inzucchi et al. Diabetes Care 2015;38:140-149. Table 7 provides recommendations for statin and combination therapy in people with diabetes. infarction, β-blockers should be continued for at least 2 years after the event. B
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• In patients with symptomatic heart failure, thiazolidinedione treatment should not be used. A • In patients with type 2 diabetes with stable congestive heart failure, metformin may be used if eGFR remains >30 mL/min but should be avoided in unstable or hospitalized patients with congestive heart failure. B
MICROVASCULAR COMPLICATIONS AND FOOT CARE
Intensive diabetes management with the goal of achieving near-normoglycemia has been shown in large, prospective, randomized studies to delay the onset and progression of microvascular complications.
Diabetic Kidney Disease
Recommendations
• At least once a year, assess urinary albumin (e.g., spot UACR) and eGFR in patients with type 1 diabetes with a duration of ≥5 years, in all patients with type 2 diabetes, and in all patients with comorbid hypertension. B 
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• Optimize glucose control to reduce the risk or slow the progression of diabetic kidney disease. A • Optimize blood pressure control to reduce the risk or slow the progression of diabetic kidney disease. A • In nonpregnant patients with diabetes and hypertension, either an ACE inhibitor or an ARB is recommended for those with modestly elevated UACR (30-299 mg/g creatinine) B and is strongly recommended for those with UACR >300 mg/g creatinine and/or eGFR <60 mL/min/1.73 m 2 . A Screening for albuminuria can be most easily performed by UACR in a random spot urine collection. UACR determined for two of three specimens collected within a 3-to 6-month period should be abnormal before considering a patient to have albuminuria.
Blood pressure levels <140/90 mmHg in diabetes are recommended to reduce CVD mortality and slow chronic kidney disease (CKD) progression.
With reduced eGFR, drug dosing may require modification. The U.S. Food and Drug Administration (FDA) revised guidance for the use of metformin in diabetic kidney disease in 2016, recommending use of eGFR instead of serum creatinine to guide treatment and expanding the pool of patients with kidney disease for whom metformin treatment should be considered. The revised FDA guidance states that metformin is contraindicated in patients with an eGFR <30 mL/min/1.73 m 2 , eGFR should be monitored while taking metformin, the benefits and risks of continuing treatment should be reassessed when eGFR falls to <45 mL/min/1.73 m 2 , metformin should not be initiated for patients with an eGFR <45 mL/min/1.73 m 2 , and metformin should be temporarily discontinued at the time of or before iodinated contrast imaging procedures in patients with an eGFR of 30-60 mL/min/1.73 m 2 . Other glucose-lowering medications also require dose adjustment or discontinuation at low eGFR.
Recommendations for the management of CKD in people with diabetes are summarized in Table 9 .
Diabetic Retinopathy
Recommendations
• Optimize glycemic control to reduce the risk or slow the progression of diabetic retinopathy. 
• Obtain a history of ulceration, amputation, Charcot foot, angioplasty or vascular surgery, cigarette smoking, retinopathy, and renal disease and assess current symptoms of neuropathy (pain, burning, numbness) and vascular disease (leg fatigue, claudication The care of older adults with diabetes is complicated by their clinical and functional heterogeneity. Providers caring for older adults with diabetes must take this heterogeneity into consideration when setting and prioritizing treatment goals (Table 10) .
Older adults with diabetes are likely to benefit from control of other cardiovascular risk factors. Evidence is strong for treatment of hypertension. There is less evidence for lipid-lowering and aspirin therapy, although the benefits of these interventions are likely to apply to older adults whose life expectancies equal or exceed the time frames of clinical prevention trials.
Pharmacologic Therapy
Special care is required in prescribing and monitoring pharmacologic therapy in older adults. Factors include hypoglycemia, cost, and coexisting conditions (e.g., renal status). The patient's living situation must be considered because it may affect diabetes management and support.
Treatment in Skilled Nursing Facilities and Nursing Homes
Management of diabetes is unique in the long-term care (LTC) setting (i.e., nursing homes and skilled nursing facilities). Individualization of health care is important for all patients. However, practical guidance is needed for both medical providers and LTC staff and caregivers.
Older adults with diabetes in LTC are especially vulnerable to hypoglycemia because of their disproportionately higher number of complications and comorbidities. Alert strategies should be in place for hypoglycemia (blood glucose ≤70 mg/dL [3.9 mmol/L]) and hyperglycemia (blood glucose >250 mg/dL [13.9 mmol/L]).
For patients in the LTC setting, special attention should be given to nutritional considerations, end-of-life care, and changes in diabetes management with respect to advanced disease. Acknowledging the limited benefit of intensive glycemic control in people with advanced disease can guide A1C goals and determine the use or withdrawal of medications. For more information, see ADA's position statement "Management of Diabetes in Long-Term Care and Skilled Nursing Facilities."
CHILDREN AND ADOLESCENTS
Children and adolescents with diabetes have unique aspects of care such as changes in insulin sensitivity related to physical growth and sexual maturation, ability to provide self-care, supervision in the child care and school environment, and neurological vulnerability to hypoglycemia and hyperglycemia (in young children), as well as possible adverse neurocognitive effects of diabetic ketoacidosis (DKA). Attention to family dynamics, developmental stages, and physiological differences related to sexual maturity are all essential in developing and implementing an optimal diabetes regimen.
Support Services
Recommendations
• Youth with type 1 diabetes and parents/caregivers (for patients <18 years of age) should receive culturally sensitive and developmentally appropriate individualized DSME and DSMS according to national standards at diagnosis and routinely thereafter. B
• 
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appropriate size cuff and with the child seated and relaxed. Lifestyle modifications, including dietary modification and increased exercise, should be implemented for 3-6 months. If target blood pressure has not been reached within 3-6 months, pharmacotherapy should be initiated.
Dyslipidemia
Recommendations
• Obtain a fasting lipid profile on children ≥10 years of age soon after diabetes diagnosis (after glucose control has been established Observational studies show an increased risk of diabetic embryopathy, especially anencephaly, microcephaly, congenital heart disease, and caudal regression directly proportional to elevations in A1C during the first 10 weeks of pregnancy. Preconception counseling visits should include rubella, syphilis, hepatitis B virus, and HIV testing, as well as Pap smear, cervical cultures, blood typing, prescription of prenatal vitamins (with at least 400 µg folic acid), and smoking cessation counseling if indicated.
Diabetes-specific testing should include A1C, thyroid-stimulating hormone, creatinine, and UACR. The medication list should be reviewed for potentially teratogenic drugs, and patients should be referred for a comprehensive eye exam. Women with preexisting diabetic retinopathy will need close monitoring during pregnancy to ensure that retinopathy does not progress.
Preconception counseling resources tailored for adolescents are available at no cost through the ADA.
Postpartum Care
Because GDM may represent preexisting undiagnosed type 2 or even type 1 diabetes, women with GDM should be tested for persistent diabetes or prediabetes at 4-12 weeks postpartum with a 75-g OGTT using the nonpregnancy criteria as outlined in the section on classification and diagnosis of diabetes above.
Because GDM is associated with increased maternal risk for diabetes, women should also be tested every 1-3 years thereafter if the 4-to 12-week 75-g OGTT is normal, with frequency of testing depending on other risk factors, including family history, prepregnancy BMI, and need for insulin or oral glucose-lowering medication during pregnancy. Ongoing evaluation may be performed with any recommended glycemic test (e.g., A1C, FPG, or 75-g OGTT using nonpregnant thresholds).
DIABETES CARE IN THE HOSPITAL, NURSING HOME, AND SKILLED NURSING FACILITY
Recommendations
• Perform an A1C for all patients with diabetes or hyperglycemia admitted to the hospital if not performed in the prior 3 months. B • Insulin therapy should be initiated for treatment of persistent hyperglycemia starting at a threshold ≥180 mg/dL (10.0 mmol/L). Once insulin therapy is started, a target glucose range of 140-180 mg/dL (7.8-10.0 mmol/L) is recommended for the majority of critically ill patients A and noncritically ill patients. C • More stringent goals such as <140 mg/dL (<7.8 mmol/L) may be appropriate for selected patients, as long as this can be achieved without significant hypoglycemia. C • Intravenous (IV) insulin infusions should be administered using validated written or computerized protocols that allow for predefined adjustments in the insulin infusion rate based on glycemic fluctuations and insulin dose. E • Basal insulin or a basal-plus-bolus-correction insulin regimen is the preferred treatment for noncritically ill patients with poor oral intake or those who are taking nothing by mouth. An insulin regimen with basal, nutritional, and correction components is the preferred treatment for noncritically ill hospitalized patients with good nutritional intake. A • Sole use of sliding-scale insulin in the inpatient hospital setting is strongly discouraged. A • A hypoglycemia management protocol should be adopted and implemented by each hospital or hospital system. A plan for preventing and treating hypoglycemia should be established for each patient. Episodes of hypoglycemia in the hospital should be documented in the medical record and tracked. E • The treatment regimen should be reviewed and changed as necessary to prevent further hypoglycemia when a blood glucose value is ≤70 mg/dL (3.9 mmol/L). C
• There should be a structured discharge plan tailored to the individual patient with diabetes. B
Considerations on Admission
Initial admission documentation should state that the patient has type 1 or type 2 diabetes or no history of diabetes. Both hyperglycemia and hypoglycemia are associated with adverse outcomes, including death. High-quality care can often be ensured by the use of structured order sets consistent with quality assurance standards.
Glycemic Targets in Hospitalized Patients
Standard Definition of Glucose Abnormalities
• Hyperglycemia: >140 mg/dL (7.8 mmol/L) • Hypoglycemia: <54 mg/dL (3.0 mmol/L) or severe cognitive impairment. (See the section on Hypoglycemia [p. 14] for additional details on the new criteria.)
A glucose value ≤70 mg/dL (3.9 mmol/L) may be used as an alert value and as a threshold for further titration of insulin regimens.
Antihyperglycemic Agents in Hospitalized Patients
In most instances in the hospital setting, insulin is the preferred treatment for glycemic control, but in certain circumstances, a previous home regimen may be continued.
Insulin Therapy
IV insulin protocols should be used for critically ill patients. Basal-bolus regimens that include correction doses and account for oral intake may be used for many noncritical-care patients. Scheduled subcutaneous insulin injections should align with meals and bedtime or be given every 4-6 hours if no meals are taken or if continuous enteral/parenteral therapy is being used.
Subcutaneous insulin should be administered 1-2 hours before IV insulin is discontinued. Converting to basal insulin at 60-80% of the P O S I T I O N S TAT E M E N T daily infusion dose has been shown to be effective. Premixed insulins are not routinely recommended for hospital use.
Standards for Special Situations
Refer to the full 2017 Standards of Care for guidance on enteral/parenteral feedings, DKA and hyperosmolar hyperglycemic state, and glucocorticoid therapy.
Perioperative Care
On the morning of surgery or a procedure, hold any oral hypoglycemic agents; give half of the patient's NPH insulin dose or 60-80% doses of long-acting analog or pump basal insulin. Monitor blood glucose every 4-6 hours while a patient is taking nothing by mouth and dose with short-acting insulin as needed with a target of 80-180 mg/dL (4.4-10.0 mmol/L).
MNT in the Hospital
The goals of MNT are to optimize glycemic control, provide adequate calories to meet metabolic demands, and address personal food preferences. The term "ADA diet" is no longer used. A registered dietitian can serve as an inpatient team member.
Transition From the Acute Care Setting
Tailor a structured discharge plan beginning at admission and update as patient needs change. It is important that patients be provided with appropriate durable medical equipment, medications, supplies, and prescriptions, along with appropriate education at the time of discharge. Psychosocial factors should be considered, including social determinants of care. An outpatient follow-up visit within 1 month of discharge is advised for all patients having hyperglycemia in the hospital. Continuing contact may also be needed. Clear communication with outpatient providers either directly or via structured hospital discharge summaries facilitates safe transitions to outpatient care. If oral medications are held in the hospital, there should be protocols for resuming them 1-2 days before discharge. Factors to prevent readmissions need to be considered. See the section above on older adults with diabetes regarding long-term care and skilled nursing facilities.
DIABETES ADVOCACY Advocacy Position Statements
For a list of ADA advocacy position statements, including "Diabetes and Driving" and "Diabetes and Employment," refer to Section 15 ("Diabetes Advocacy") of the complete 2017 Standards.
